BRIC-inStem conducts first gene therapy trial for Haemophilia

BRIC-inStem conducts first gene therapy trial for Haemophilia

Union Minister for Science and Technology Dr Jitendra Singh inspected the various facilities at BRIC-inStem and reviewed ongoing clinical trials in collaboration  Biotechnology Industry Research Assistance Council’s Institute for Stem Cell Science and Regenerative Medicine (BRIC-inStem) in collaboration with CMC Vellore and other medical institutions and hospitals has conducted the first gene therapy trial for Haemophilia.  Union Minister for Sc…

Sydney – The two approved gene therapies for hemophilia B have so far fulfilled their promise of permanently protecting patients from severe bleeding. This is demonstrated by current experience with etranacogene dezaparvovec after 4 years and with fidanacogene elaparvovec after up to 6 years. Hemophilia B was one of the first diseases...